MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings (MGTX) filed a Form 144 notice for the proposed sale of 47,500 ordinary shares under Rule 144. The filing lists an aggregate market value of $398,525 and an approximate sale date of 10/07/2025. The broker named is Merrill Lynch, 200 Park Avenue, New York, NY 10166, and the shares are listed on NASDAQ.
The securities to be sold were acquired on 06/07/2018 via an incentive compensation stock grant from the issuer, with 47,500 shares acquired on that date. As context, the filing states 80,447,477 shares were outstanding.
MeiraGTx reported continued operating losses as it advances its gene-therapy pipeline and manufacturing business. For the six months ended June 30, 2025 the company recorded a $78.8 million net loss and used $80.8 million of cash from operations. Cash, cash equivalents and restricted cash totaled $34.4 million at June 30, 2025 and the balance sheet showed a $780.8 million accumulated deficit, leaving shareholders' equity at $3.0 million.
Strategically, MeiraGTx signed a March 9, 2025 collaboration with Hologen that contemplates a $200 million upfront payment and up to $230 million of additional funding; Hologen made a $6.0 million payment in June 2025 and an additional $17.0 million payment in the third quarter of 2025, and the parties expect the transaction to close in the third calendar quarter of 2025, subject to customary conditions. The company also retains a supply agreement and contingent payments tied to the prior asset sale to Johnson & Johnson (an initial $65.0 million upfront in 2023 and $60.0 million in milestones received in 2024, with up to $350.0 million of contingent consideration remaining). Management states available cash, receivables, the $17.0 million deposit received and anticipated remaining collaboration proceeds are expected to be sufficient to fund operations for at least the next twelve months.
MeiraGTx Holdings plc furnished an 8-K after releasing its financial results for the quarter ended June 30, 2025. The company reported these quarterly results in a press release dated August 14, 2025, which is attached as Exhibit 99.1 and incorporated by reference. The press release and related materials are designated as furnished rather than filed, meaning they are not subject to certain Exchange Act liability provisions unless specifically incorporated into other filings.
MeiraGTx Holdings plc (MGTX) – Form 4 insider transaction
President & CEO Alexandria Forbes reported the sale of 47,500 ordinary shares of MGTX on 8 July 2025. The shares were disposed of at a weighted-average price of $7.97 per share (individual trade prices ranged from $7.73 to $8.15). The transaction was executed under a Rule 10b5-1 trading plan adopted 21 Aug 2024, indicating it was pre-scheduled and not the result of ad-hoc decision-making.
Following the sale, Forbes’ direct beneficial ownership stands at 1,361,483 ordinary shares. No derivative securities were involved in this filing, and no additional transactions were reported.
The gross proceeds of the reported sale, based on the disclosed weighted-average price, total roughly $379 thousand. Forbes continues to serve as both Director and President & CEO of MeiraGTx.
Form 144 filing overview for MeiraGTx Holdings plc (MGTX)
The notice discloses a proposed sale of 47,500 ordinary shares through Merrill Lynch, 200 Park Avenue, New York, NY 10166. The transaction is scheduled for approximately 08 July 2025 on the NASDAQ exchange.
- Aggregate market value: $378,575
- Total shares outstanding: 80,365,359
- Percentage of float affected: ≈0.06%
The shares were originally acquired via incentive compensation stock grants on 02 March 2018 (35,625 shares) and 07 June 2018 (11,875 shares). The filer reports no other share sales within the past three months.
Because the sale represents a small fraction of outstanding stock and stems from equity compensation, the filing is generally considered routine. Investors often monitor Form 144s to gauge insider sentiment; however, the scale here is unlikely to materially impact market dynamics.
SEC Form 4 for MeiraGTx Holdings plc (MGTX) discloses that Richard Giroux, the company’s Chief Financial & Operating Officer, gifted 5,000 ordinary shares on 06/30/2025 (transaction code G, price $0). After this transaction, Giroux still owns 877,494 shares directly and 90,152 shares indirectly (5,152 via spouse; 85,000 via Aigle Healthcare Partners III LLC). No derivative positions were added or reduced, and the filing was signed on 07/02/2025. The Rule 10b5-1 checkbox is not marked, indicating the gift was not executed under a preset trading plan. The transaction reduces Giroux’s direct stake by approximately 0.6%, leaving his overall ownership essentially unchanged. There is no indication of operational or financial impact on MeiraGTx arising from this personal transfer.
MeiraGTx (NASDAQ:MGTX) filed an 8-K Regulation FD disclosure announcing it has obtained all required UK foreign-direct-investment clearances for its previously announced transactions with Hologen Ltd., signed March 9 2025.
The clearance removes the final regulatory hurdle, allowing the deal—which management expects to close in July 2025—to proceed to funding and execution.